AbbVie reported 4Q diluted EPS of $2.92, which came in ahead of analysts’ estimates of $2.
AbbVie (ABBV) has announced that it has submitted applications to the U.S.
AbbVie announced that it has signed an exclusive global collaboration agreement with I-Mab to develop and sell the Chinese biotech company’s lemzoparlimab drug …
The COVID-19 pandemic has led to a wake-up call for governments, as they realize the significant investment required by the healthcare sector. Billions …
AbbVie’s (ABBV) Allergan has told Molecular Partners that it will withdraw application filings with both the European Medicines Agency (EMA) and the Japanese …
AbbVie (ABBV) and Roche’s (RHHBY) Genentech have revealed positive results from the Phase III VIALE-A study, evaluating Venclexta (venetoclax) with azacitidine in people with …
Shares in Genmab A/S (GMAB) rose in pre-market trading after announcing a collaboration agreement with AbbVie (ABBV) to jointly develop and commercialize three …
Biopharma AbbVie (ABBV) has announced positive Phase 3 data from a Select-Choice clinical trial, comparing Rinvoq (upadacitinib, 15 mg, once daily) to Bristol-Myers …
After several postponed decisions, Mylan Inc (MYL) has announced that it is moving forward with a Botox biosimilar development program in collaboration with …
By Amber Hestla This past weekend, I had a chance to talk to a friend who’s been trading financial markets for more than …
